ReviewFrontiers in oncology2022
Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 8 citations in OpenAlex.
- Synchronous diagnosis of multicentric glioma with distinct isocitrate dehydrogenase molecular profiles: a case report.CNS oncology · 2026Article
- Synchronous Multicentric WHO grade 3 Oligodendroglioma and WHO grade 3 Astrocytoma : A Case Report and Literature Review.Journal of Korean Neurosurgical Society · 2026Article
- Distal noncontiguous recurrence and sarcomatous transformation of glioblastoma with stable molecular profile: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Extra-central nervous system metastasis from high-grade glioma: a single-institution experience.Journal of neuro-oncology · 2025Article
- Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated.Acta neuropathologica communications · 2025Article
- Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine.Cell death discovery · 2024Review
- General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67.Medicina (Kaunas, Lithuania) · 2023Article
- Unraveling the Complexity of Multicentric Gliomas: Insights Into Chronicity and Genetic Aberrations.Cureus · 2023Article
- Case Report: Brain tumor's pitfalls: two cases of high-grade brain tumors mimicking autoimmune encephalitis with positive onconeuronal antibodies.Frontiers in oncology · 2023Article
- A single-institution retrospective study of multicentric gliomas stratified byNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a special type of glioma, multicentric glioma provides an ideal pathological model for glioma research. According to the stem-cell-origin theory, multiple lesions of multicentric glioma share the same neuro-oncological origin, both in gene level and in cell level. Although the number of studies focusing on genetic evolution in gliomas with the model of multicentric gliomas were limited, some mutations, including IDH1 mutations, TERTp mutations and PTEN deletions, are found to be at an early stage in the process of genetic aberrance during glioma evolution based on the results of these studies. This article reviews the clinical reports and genetic studies of multicentric glioma, and intends to explain the various clinical phenomena of multicentric glioma from the perspective of genetic aberrance accumulation and tumor cell evolution. The malignant degree of a glioma is determined by both the tumorigenicity of early mutant genes, and the stemness of early suffered cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.